Eli Lilly and Company
LLY
Hisse Senetlerindeki Sıralama
#12
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Hisse Fiyatı
$1,292.37
Piyasa Değeri
$1.217T
Değişim (1 gün)
3.94%
Değişim (1 yıl)
61.62%
Ülke
US
Ticaret Eli Lilly and Company (LLY)
Kategori
Healthcare
Eli Lilly and Company (LLY) için gelir
Dec 2025 itibarıyla gelir TTM: $65.18B
Eli Lilly and Company şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $65.18B'dir. 2024 yılında şirketin geliri $45.04B önceki yıla göre artış 2023 yılındaki $34.12B gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Eli Lilly and Company için 2000 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $65.18B | 0.00% |
| 2025 | $65.18B | 44.71% |
| 2024 | $45.04B | 32.00% |
| 2023 | $34.12B | 19.56% |
| 2022 | $28.54B | 16.31% |
| 2020 | $24.54B | 14.17% |
| 2018 | $21.49B | 7.61% |
| 2017 | $19.97B | -5.88% |
| 2016 | $21.22B | 6.33% |
| 2015 | $19.96B | 1.75% |
| 2014 | $19.62B | -15.13% |
| 2013 | $23.11B | 2.25% |
| 2012 | $22.60B | -6.93% |
| 2011 | $24.29B | 5.25% |
| 2010 | $23.08B | 5.68% |
| 2009 | $21.84B | 7.19% |
| 2008 | $20.37B | 9.33% |
| 2007 | $18.63B | 18.75% |
| 2006 | $15.69B | 7.14% |
| 2005 | $14.65B | 5.68% |
| 2004 | $13.86B | 10.14% |
| 2003 | $12.58B | 13.59% |
| 2002 | $11.08B | -4.03% |
| 2001 | $11.54B | 6.26% |
| 2000 | $10.86B | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| $99.34B | 52.40% |
US
|
|
| $64.39B | -1.22% |
US
|
|
| $66.40B | 1.87% |
US
|
|
| $77.52B | 18.93% |
CH
|
|
| $56.26B | -13.69% |
CH
|
